Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $4.5 million.

  • Fulcrum Therapeutics' Net Cash Flow rose 13184.5% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year decrease of 15989.83%. This contributed to the annual value of $32.8 million for FY2024, which is 44355.53% up from last year.
  • Fulcrum Therapeutics' Net Cash Flow amounted to $4.5 million in Q3 2025, which was up 13184.5% from $414000.0 recorded in Q2 2025.
  • Fulcrum Therapeutics' Net Cash Flow's 5-year high stood at $50.8 million during Q3 2022, with a 5-year trough of -$55.8 million in Q4 2022.
  • For the 5-year period, Fulcrum Therapeutics' Net Cash Flow averaged around -$519210.5, with its median value being -$768000.0 (2023).
  • Examining YoY changes over the last 5 years, Fulcrum Therapeutics' Net Cash Flow showed a top increase of 618958.33% in 2024 and a maximum decrease of 26250.64% in 2024.
  • Fulcrum Therapeutics' Net Cash Flow (Quarter) stood at -$30.1 million in 2021, then plummeted by 85.76% to -$55.8 million in 2022, then surged by 91.91% to -$4.5 million in 2023, then crashed by 219.19% to -$14.4 million in 2024, then skyrocketed by 131.11% to $4.5 million in 2025.
  • Its Net Cash Flow stands at $4.5 million for Q3 2025, versus $414000.0 for Q2 2025 and -$16.0 million for Q1 2025.